<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Abbassi RH</submitter><funding>Cancer Institute NSW</funding><pagination>402-413</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7089104</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>2(6)</volume><pubmed_abstract>Sensitivity to microtubule-targeting agents (MTAs) varies among cancers and predicting the response of individual cancer patients to MTAs remains challenging. As microtubules possess vast molecular heterogeneity generated by tubulin isotypes and their post-translational modifications, we questioned whether this heterogeneity can impact MTA sensitivity. We investigated microtubule heterogeneity in 15 glioblastoma cell lines and measured sensitivity of orthogonal MTAs using a per-division growth rate inhibition method that corrects for the confounding effects of variable cell proliferation rates. We found that the tubulin profile is unique for each glioblastoma cell line and that the total α- and β-tubulin levels impact on MTA sensitivity. The baseline levels of α- and β-tubulin were up to 2</pubmed_abstract><journal>ACS pharmacology &amp; translational science</journal><pubmed_title>Lower Tubulin Expression in Glioblastoma Stem Cells Attenuates Efficacy of Microtubule-Targeting Agents.</pubmed_title><pmcid>PMC7089104</pmcid><funding_grant_id>2015/CDF107</funding_grant_id><pubmed_authors>Stringer BW</pubmed_authors><pubmed_authors>Abbassi RH</pubmed_authors><pubmed_authors>Munoz L</pubmed_authors><pubmed_authors>Indurthi DC</pubmed_authors><pubmed_authors>Recasens A</pubmed_authors><pubmed_authors>Johns TG</pubmed_authors><pubmed_authors>Day BW</pubmed_authors></additional><is_claimable>false</is_claimable><name>Lower Tubulin Expression in Glioblastoma Stem Cells Attenuates Efficacy of Microtubule-Targeting Agents.</name><description>Sensitivity to microtubule-targeting agents (MTAs) varies among cancers and predicting the response of individual cancer patients to MTAs remains challenging. As microtubules possess vast molecular heterogeneity generated by tubulin isotypes and their post-translational modifications, we questioned whether this heterogeneity can impact MTA sensitivity. We investigated microtubule heterogeneity in 15 glioblastoma cell lines and measured sensitivity of orthogonal MTAs using a per-division growth rate inhibition method that corrects for the confounding effects of variable cell proliferation rates. We found that the tubulin profile is unique for each glioblastoma cell line and that the total α- and β-tubulin levels impact on MTA sensitivity. The baseline levels of α- and β-tubulin were up to 2</description><dates><release>2019-01-01T00:00:00Z</release><publication>2019 Dec</publication><modification>2025-04-21T20:14:00.232Z</modification><creation>2025-04-05T17:52:06.53Z</creation></dates><accession>S-EPMC7089104</accession><cross_references><pubmed>32259073</pubmed><doi>10.1021/acsptsci.9b00045</doi></cross_references></HashMap>